MRG 003
Phase 2Small molecule
MRG 003 is one of 15 small molecule programs targeting Salivary Gland Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Salivary Gland Cancer
#DrugCompanyPhaseTrials
1Zoladex
TTerSera Therapeutics LLC
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Keytruda
Merck & Co.Phase 2
Navmi
SSummit Therapeutics
Phase 2
Alimta
EEagle Pharmaceuticals, Inc.
Phase 2
Pucotenlimab
SSun Yat-sen University
Phase 2
Casodex
IIstituto Clinico Humanitas
Preclinical
Xpovio
KKaryopharm Therapeutics Inc
Preclinical
Leuprorelin
TakedaPreclinical
MRG 003
JJi Dongmei
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRG 003. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- JJi Dongmei